Delayed emesis: moderately emetogenic chemotherapy.
Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT(3) antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.
Roila
Fausto
F
Medical Oncology Division, Policlinico Hospital, 06122 Perugia, Italy. roila.fausto@libero.it
Warr
David
D
Clark-Snow
Rebecca A
RA
Tonato
Maurizio
M
Gralla
Richard J
RJ
Einhorn
Lawrence H
LH
Herrstedt
Jorn
J
D000932:Antiemetics / Q000592:standards / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000145:classification; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000592:standards / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000592:standards / Q000627:therapeutic use; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D017410:Practice Guidelines as Topic; D058831:Serotonin 5-HT3 Receptor Antagonists; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D018492:Dopamine Antagonists; D058831:Serotonin 5-HT3 Receptor Antagonists; D003907:Dexamethasone